Spectrum Pharmaceuticals' Board of Directors Re-Elected at Annual Stockholders Meeting

IRVINE, Calif.--(Business Wire)--
Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI) announced today
that shareholders re-elected all six of the Company's nominees to the
Board of Directors, with more than 88 percent of votes cast, at the
Annual Meeting of Stockholders held on Friday, June 20, 2008 at the
Company's global corporate headquarters in Irvine, California. Each of
the directors will serve for a one-year term. The directors are Mr.
Mitchell P. Cybulski, Mr. Richard D. Fulmer, Dr. Stuart M. Krassner,
Mr. Anthony E. Maida III, Dr. Rajesh C. Shrotriya, and Dr. Julius A.
Vida.

"I would like to thank the shareholders for their support as we
continue to transform into a commercial pharmaceutical company," said
Rajesh C. Shrotriya, Chairman, Chief Executive Officer, and President.
"We continue to prepare for the launch of Fusilev(TM), our first
proprietary oncology drug. We are awaiting final approval of packaging
and labeling from the FDA. At the same time, we continue to focus on
advancing our drug portfolio through the development process."

BIOGRAPHIES

Mitchell P. Cybulski, M.B.A.

Mitchell P. Cybulski, has been a director of Spectrum since July
2007. From 1993 to his retirement in 2000, Mr. Cybulski served as
Chairman of the international business of SmithKline Beecham Plc., a
pharmaceutical company, with responsibility for all pharmaceutical,
vaccine and consumer sales for all territories outside of North
America and Europe. Mr. Cybulski served as President Japan/Pacific for
SmithKline Beecham Plc. from 1991 to 1993, with responsibility for
pharmaceutical and vaccine businesses in Southeast Asia, China, Japan,
Australia and New Zealand. From 1985 to 1991, he served as President,
Japan, for Bristol-Myers Squibb. From 1982 to 1985, Mr. Cybulski
served as President of Mead Johnson, Canada, a subsidiary of
Bristol-Myers. Before holding that position, he served in various
capacities in finance and general management at Bristol-Myers.
Mr. Cybulski sits on the boards of several private companies,
including bio-tech and medical device companies. Mr. Cybulski is a
graduate of the University of Texas at Arlington and holds an M.B.A.
from Columbia University.

Richard D. Fulmer, M.B.A.

Mr. Fulmer, has been a director of Spectrum since September 2005.
His career spans over thirty years, including twenty-four years spent
at Pfizer, Inc., a NYSE listed pharmaceutical company, where he held
senior positions in marketing, business development, and general
management. Mr. Fulmer retired from Pfizer in 2001 and since that time
has served as a business advisor to privately held companies in the
pharmaceutical industry. From 1998 until his retirement, Mr. Fulmer
was Vice President and General Manager of Pfizer's US Veterinary
healthcare business, with accountability for the management of sales,
marketing, and medical operations. Prior to that assignment,
Mr. Fulmer served as Pfizer's Vice President for Licensing and
Development from 1993 to 1997, with responsibility for corporate
licensing and business development activity, which included the
acquisition of new drugs and technology for the global pharmaceutical
business. Chief among his accomplishments was the formation of a
strategic alliance with Eisai for the Alzheimer's drug Aricept. He
also led the effort to license the cholesterol reduction product
Lipitor, and was responsible for creating a multi-company alliance for
the development of Exubera, a pulmonary insulin product. During his
tenure in licensing, he became a prominent speaker at industry
conferences and a member of the Licensing Executive Society.
Mr. Fulmer was also a Vice President of Marketing for Pfizer where he
played a key role in the introduction and commercial success of
several market leading drugs, including Diflucan, Zoloft, and
Glucotrol. Prior to joining Pfizer, Mr. Fulmer was a Senior Financial
Analyst for the Ford Motor Company and served as a Captain in the
United States Marine Corps. He received an MBA in Finance from George
Washington University in 1973. He also holds a B.S. in Economics from
the University of Oregon (1967) and a Diploma in International
Business from the Netherlands School of Business, Nijenrode
University.

Stuart M. Krassner, Sc.D., Psy.D.

Dr. Krassner, has been a director of Spectrum since December 2004
and was previously a member of our Scientific Advisory Board from 1996
to 2001. Dr. Krassner's career spans four decades of experience in
various positions at the University of California, Irvine (UCI), most
recently as Professor Emeritus of Developmental and Cell Biology at
the School of Biological Sciences. While at UCI, he developed and
reinforced FDA and NIH compliance procedures for UCI-sponsored human
clinical trials, established UCI's first Institutional Review Board,
and at one time headed all contract and grant activities. Dr. Krassner
has also been retained by a number of public and private
pharmaceutical, medical device and other companies to provide
scientific and regulatory advisory services, including FDA compliance.
Dr. Krassner's work has been published in numerous peer-reviewed U.S.
journals. Dr. Krassner has been awarded grants from the National
Institute of Health, the National Science Foundation and the World
Health Organization. Dr. Krassner has been a member of the American
Society of Protozoology, the American Society of Tropical Medicine and
Hygiene, the Corporation of the Marine Biological Laboratories, Woods
Hole, MA, and Sigma Xi, among others. Dr. Krassner received his Sc.D.
from the Bloomberg School of Public Health at Johns Hopkins
University. He holds a B.S. in Biology from Brooklyn College.

Anthony E. Maida, III, M.A., M.B.A.

Mr. Maida, has been a director of Spectrum since December 2003.
Mr. Maida has been the Acting Chairman of Dendri Therapeutics, Inc., a
startup company focused on the clinical development of therapeutic
vaccines for patients with cancer, since 2003. Mr. Maida has been
serving as Chairman, Founder and Director of BioConsul Drug
Development Corporation since 1999, providing consulting services to
large and small biopharmaceutical firms in the clinical development of
oncology products and product acquisitions and to venture capital
firms evaluating life science investment opportunities. Additionally,
Mr. Maida also serves as a member of the Board of Directors of Sirion
Therapeutics, Inc., a private ophthalmic-focused company. Mr. Maida
served as the President and Chief Executive Officer of Replicon
NeuroTherapeutics, Inc., a biopharmaceutical company focused on the
therapy of patients with tumors (both primary and metastatic) of the
central nervous system (CNS), where he successfully raised financing
from both venture capital and strategic investors and was responsible
for all financial and operational aspects of the company, from June
2001 to July 2003. From 1999 to 2001, Mr. Maida held positions as
Interim Chief Executive Officer for Trellis Bioscience, Inc., a
private biotechnology company that addresses high clinical stage
failure rates in pharmaceutical development, and CancerVax
Corporation, a biotechnology company dedicated to the treatment of
cancer. From 1992 until 1999, Mr. Maida served as President and CEO of
Jenner Biotherapies, Inc., a biopharmaceutical company. From 1980 to
1992, Mr. Maida served in senior management positions with various
companies including President and Chief Executive Officer of Cell
Path, Inc., a biosciences company specializing in drug discovery and
development, and Vice President Finance and Chief Financial Officer of
Data Plan, Inc., a wholly owned subsidiary of Lockheed Corporation.
Additionally, Mr. Maida currently performs research in the laboratory
of Kit S. Lam, M.D., Ph.D., University of California, Medical Center,
Department of Hematology and Oncology, where he is completing his
doctoral work in immunology (advanced to Doctoral Candidacy).
Mr. Maida serves on the Advisory Boards of EndPoint BioCapital, Sdn
Bhd (Kuala Lumpur, Malaysia) and Innovera Life Science Fund and serves
as a consultant and technical analyst for several investment firms,
including CMX Capital, LLC, Sagamore Bioventures, Roaring Fork
Capital, North Sound Capital, and vFinance. Additionally, Mr. Maida
has been retained by Abraxis BioScience, Inc., Northwest
Biotherapeutics, Inc., Takeda Chemical Industries, Ltd. (Osaka,
Japan), Novel Bioventures and Toucan Capital to conduct corporate and
technical due diligence on investment opportunities. Mr. Maida is a
speaker at industry conferences and is a member of the American
Society of Clinical Oncology, the American Association for Cancer
Research, the Society of Neuro-Oncology, the International Society for
Biological Therapy of Cancer, the American Association of
Immunologists and the American Chemical Society and the Society of
Toxicology. Mr. Maida received a B.A. Degree in History from
University of Santa Clara in 1975, received a B.A. degree in Biology
from San Jose State University in 1977, a M.B.A. from the University
of Santa Clara in 1978, and received a M.A. in toxicology from
San Jose University in 1986.

Rajesh C. Shrotriya, M.D.

Dr. Shrotriya, has been Chairman of the Board, Chief Executive
Officer and President since August 2002 and a director of Spectrum
since June 2001. From September 2000 to August 2002, Dr. Shrotriya
served as President and Chief Operating Officer of Spectrum.
Dr. Shrotriya also serves as a member of the Board of Directors of
Antares Pharma, Inc., an AMEX listed drug delivery systems company.
Prior to joining Spectrum, Dr. Shrotriya held the position of
Executive Vice President and Chief Scientific Officer from November
1996 until August 2000, and as Senior Vice President and Special
Assistant to the President from November 1996 until May 1997, for
SuperGen, Inc., a publicly-held pharmaceutical company focused on
drugs for life-threatening diseases, particularly cancer. From August
1994 to October 1996, Dr. Shrotriya held the positions of Vice
President, Medical Affairs and Vice President, Chief Medical Officer
of MGI Pharma, Inc., an oncology-focused biopharmaceutical company.
Dr. Shrotriya spent 18 years at Bristol-Myers Squibb Company in a
variety of positions, most recently as Executive Director, Worldwide
CNS Clinical Research. Previously, Dr. Shrotriya held various
positions at Hoechst Pharmaceuticals, most recently as Medical
Advisor. Dr. Shrotriya was an attending physician and held a courtesy
appointment at St. Joseph Hospital in Stamford, Connecticut. In
addition, he received a certificate for Advanced Biomedical Research
Management from Harvard University. Dr. Shrotriya received his M.D.
degree from Grant Medical College, Bombay, India, in 1974; his
D.T.C.D. (Post Graduate Diploma in Chest Diseases) degree from Delhi
University, V.P. Chest Institute, Delhi, India, in 1971; M.B.B.S.
(Bachelor of Medicine and Bachelor of Surgery -- equivalent to an M.D.
degree in the U.S.) from the Armed Forces Medical College, Poona,
India, in 1967; and a B.S. with Chemistry degree from Agra University,
Aligarh, India, in 1962.

Julius A. Vida, Ph.D. M.B.A.

Dr. Vida, has been a director of Spectrum since April 2003. Since
1993, Dr. Vida has been a self-employed pharmaceutical consultant with
VIDA International Pharmaceutical Consultants. From 1975 until his
retirement in 1993, Dr. Vida held various positions at Bristol-Myers
Squibb and its predecessors. From 1991 to 1993, Dr. Vida was Vice
President, Business Development, Licensing and Strategic Planning, and
from 1985 to 1991, he was Vice President, Licensing. Dr. Vida serves
as a member of the Board of Directors of Medarex, Inc., a NASDAQ
listed company focused on the discovery and development of human
antibody-based therapeutic products and FibroGen, Inc., a private
pharmaceutical company. Dr. Vida graduated from Pazmany Peter
University, Budapest, Hungary, holds an M.S. and a Ph.D. in Organic
Chemistry from Carnegie Institute of Technology, was a R.B. Woodward
Postdoctoral Fellow at Harvard University, and holds an M.B.A. from
Columbia University.

About Spectrum Pharmaceuticals

We are a biopharmaceutical company that acquires, develops and
commercializes a diversified portfolio of drug products, with a focus
mainly on oncology and urology. Our strategy is comprised of acquiring
and developing a broad and diverse pipeline of late-stage clinical and
commercial products; establishing a commercial organization for our
approved drugs; continuing to build a team with people who have
demonstrated skills, passion, commitment and have a track record of
success in developing drugs and commercialization in our areas of
focus, and; leveraging the expertise of partners around the world to
assist us in the execution of our strategy. For more information,
please visit our website at www.spectrumpharm.com.

Forward-looking statement - This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements include but are not limited to statements that relate
to our business and its future, Spectrum's ability to identify,
acquire, develop and commercialize its portfolio of drug candidates,
the Company's promising pipeline, and any statements that relate to
the intent, belief, plans or expectations of Spectrum Pharmaceuticals,
its management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility that
our existing and new drug candidates may not prove safe or effective,
the possibility that our existing and new drug candidates, may not
receive approval from the FDA or the EMEA, and other regulatory
agencies in a timely manner or at all, the possibility that our
existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our lack of revenues, our limited
marketing experience, our dependence on third parties for clinical
trials, manufacturing, distribution and quality control and other
risks that are described in further detail in the Company's reports
filed with the Securities and Exchange Commission. We do not plan to
update any such forward-looking statements and expressly disclaim any
duty to update the information contained in this press release except
as required by law.

SPECTRUM PHARMACEUTICALS, INC.(R) is a registered trademark of
Spectrum Pharmaceuticals, Inc., TURNING INSIGHTS INTO HOPE(TM) and the
Spectrum Pharmaceuticals logos are trademarks owned by Spectrum
Pharmaceuticals, Inc.

(C) 2008 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

Spectrum Pharmaceuticals, Inc.
Russell Skibsted
SVP & Chief Business Officer
949-788-6700, x234
or
Paul Arndt
Manager, Investor Relations
949-788-6700, x216

Copyright Business Wire 2008